Loading...
In the landmark ACCORD trial, older patients with longstanding type 2 diabetes were randomized to various intensities of glycemic control, blood pressure (BP) control, and lipid management. The first round of published results dealt with so-called “macrovascular outcomes” — myocardial infarction, stroke, and cardiovascular death (JW Gen Med Jun 6 2008, JW Cardiol Mar 14 2010, and JW Cardiol Mar 14 2010; also JW Gen Med Dec 30 2010). In 2010, data on microvascular outcomes were published.
In the glycemic-control arm of the study, patients were randomized to intensive or standard treatment, which resulted in mean glycosylated hemoglobin (HbA1c) levels of 6.4% and 7.5%, respectively. The primary composite microvascular endpoint included both re…